How do we manage cardiopulmonary bypass coagulopathy?

Transfusion

Volumn 54, Issue 9, 2014, Pages 2158-2166

  Welsh, Kerry J ^a   Nedelcu, Elena ^a   Bai, Yu ^a   Wahed, Amer ^a   Klein, Kimberly ^a   Tint, Hlaing ^a   Gregoric, Igor ^b   Patel, Manish ^b   Kar, Biswajit ^b   Loyalka, Pranav ^b   Nathan, Sriram ^b   Loubser, Paul ^a   Weeks, Phillip A ^c   Radovancevic, Rajko ^b   Nguyen, Andy N D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN;

ARTICLE; BLOOD; BLOOD CELL COUNT; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD COMPONENT; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS COAGULOPATHY; CARDIOVASCULAR SURGERY; COAGULATION BASED HEMOTHERAPY; CONSULTATION; DECISION SUPPORT SYSTEM; HEALTH EDUCATION; HEART GRAFT; HEMOSTASIS; HUMAN; LABORATORY TEST; LEFT VENTRICULAR ASSIST DEVICE; OPERATING ROOM; OUTCOME ASSESSMENT; PATHOLOGIST; PATHOLOGY; PEROPERATIVE CARE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; RAPID TEST; THROMBOELASTOGRAPHY; ALGORITHM; BLOOD COAGULATION DISORDERS; CARDIOPULMONARY BYPASS;

ALGORITHMS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; CARDIOPULMONARY BYPASS; HUMANS; THROMBELASTOGRAPHY;

EID: 84908204596     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12751     Document Type: Article

References (36)

1. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.
2. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56: 824-34.
3. McKenna R, Bachmann F, Whittaker B, et al. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298-308.
4. Whitlock R, Crowther MA, Ng HJ. Bleeding in cardiac surgery: its prevention and treatment-an evidence-based review. Crit Care Clin 2005;21:589-610.
5. Valen G, Eriksson E, Risberg B, et al. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 1994;8:324-30.
6. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997;64:1120-5.
7. McKenna DH Jr, Eastlund T, Segall M, et al. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 2002;21: 1218-24.
8. Moazami N, Itescu S, Williams MR, et al. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 1998;17:876-80.
9. Goldstein DJ, Beauford RB. Left ventricular assist devices and bleeding: adding insult to injury. Ann Thorac Surg 2003;75:S42-7.
10. Drakos SG, Stringham JC, Long JW, et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg 2007;133: 1612-9.
11. Bracey AW, Reyes MA, Chen AJ, et al. How do we manage patients treated with antithrombotic therapy in the perioperative interval. Transfusion 2011;51:2066-77.
12. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120:2954-62.
13. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008;111:4871-9.
14. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. Plos One 2013;8:e78696.
15. Young G, Yonekawa KE, Nakagawa PA, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007;18: 547-53.
16. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50.
17. Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012;87:S119-S26.
18. Perzborn E, Heitmeier S, Laux V, et al. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014;133:671-81.
19. Machin DA, Allsager C. Principles of cardiopulmonary bypass. Contin Educ Anaesth Crit Care Pain 2006;6:176-81.
20. Reed G, Hoffman E, Kumar A, et al. Platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting. J Am Coll Cardiol 2012;60:B210-11.
21. American Red Cross. Practice guidelines for blood transfusion: a compilation from recent peer-reviewed literature. 2nd ed. American Red Cross, 2007.
22. Levy JH, Tanaka KA. Management of surgical hemostasis: systemic agents. Vascular 2008;16(Suppl 1):S14-21.
23. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007;83:S27-86.
24. Huang RSP, Nedelcu E, Bai Y, et al. Mobile computing platform with decision-support modules for hemotherapy. Am J Clin Pathol 2014;141:834-40.
25. Nedelcu N, Gregoric ID, Radovancevic R, et al. Intraoperative coagulation-based hemotherapy protocol decreases overall blood utilization with left ventricular assist device implantation. ASAIO. Chicago, IL, 2013.
26. Matthews JC, Pagani FD, Haft JW, et al. Model for endstage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 2010;121:214-20.
27. Schaffer JM, Arnaoutakis GJ, Allen JG, et al. Bleeding complications and blood product utilization with left ventricular assist device implantation. Ann Thorac Surg 2011;91: 740-7; discussion 747-9.
28. Castillo B, Nedelcu E, Wahed A, et al. Intraoperative coagulation-based hemotherapy protocol decreases reoperation due to postoperative bleeding complications with left ventricular assist device implantation AABB Annual Meeting. Denver, CO, 2013.
29. Tormey CA, Smith BR. The transfusion medicine specialist as a coagulation consultant: a new variant of therapeutic pathology. Transfusion 2013;53:2086-93.
30. Marques MB, Fritsma GA, Long JA, et al. Clinical pathology consultation improves coagulation factor utilization in hospitalized adults. Am J Clin Pathol 2003;120:938-43.
31. Johansson PI. The blood bank: from provider to partner in treatment of massively bleeding patients. Transfusion 2007;47:176S-181S; discussion 182S-183S.
32. AuBuchon JP. The role of transfusion medicine physicians. A vanishing breed? Arch Pathol Lab Med 1999;123:663-7.
33. American Society for Clinical Pathology. Pathology's future: a view from leaders in health care. 2010. [cited 2013 Dec 16]. Available from: http://www.ascpresources.org/e-books/future/files/future.pdf.
34. MacMillan DH, Soderberg BL, Laposata M. Regulations regarding reflexive testing and narrative interpretations in laboratory medicine. Am J Clin Pathol 2001;116(Suppl): S129-32.
35. Grzybicki DR, Raab SS. Measuring health care performance: identification and standardization of laboratory quality indicators. Am J Clin Pathol 2006;126:S48-S52.
36. McDonald JM, Smith JA. Value-added laboratory medicine in an era of managed care. Clin Chem 1995;41: 1256-62.